On Tuesday, UroGen Pharma Ltd (NASDAQ: URGN) was -3.11% drop from the session before settling in for the closing price of $14.49. A 52-week range for URGN has been $3.42 – $18.15.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 10.39% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 1.54%. With a float of $39.62 million, this company’s outstanding shares have now reached $46.10 million.
In an organization with 235 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 89.68%, operating margin of -117.51%, and the pretax margin is -147.23%.
UroGen Pharma Ltd (URGN) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward UroGen Pharma Ltd stocks. The insider ownership of UroGen Pharma Ltd is 14.08%, while institutional ownership is 96.76%. The most recent insider transaction that took place on Jun 09 ’25, was worth 38,044. In this transaction Chief Medical Officer of this company sold 5,162 shares at a rate of $7.37, taking the stock ownership to the 153,378 shares. Before that another transaction happened on Jun 09 ’25, when Company’s Officer proposed sale 5,162 for $7.37, making the entire transaction worth $38,044.
UroGen Pharma Ltd (URGN) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.63 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 1.54% per share during the next fiscal year.
UroGen Pharma Ltd (NASDAQ: URGN) Trading Performance Indicators
You can see what UroGen Pharma Ltd (URGN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.47. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.05.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.18, a number that is poised to hit -0.83 in the next quarter and is forecasted to reach -1.08 in one year’s time.
Technical Analysis of UroGen Pharma Ltd (URGN)
Let’s dig in a bit further. During the last 5-days, its volume was 1.11 million. That was inferior than the volume of 1.61 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 66.92%.
During the past 100 days, UroGen Pharma Ltd’s (URGN) raw stochastic average was set at 87.12%, which indicates a significant increase from 52.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.82 in the past 14 days, which was lower than the 0.88 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.09, while its 200-day Moving Average is $10.95. However, in the short run, UroGen Pharma Ltd’s stock first resistance to watch stands at $14.50. Second resistance stands at $14.97. The third major resistance level sits at $15.32. If the price goes on to break the first support level at $13.68, it is likely to go to the next support level at $13.33. Assuming the price breaks the second support level, the third support level stands at $12.86.
UroGen Pharma Ltd (NASDAQ: URGN) Key Stats
There are 46,107K outstanding shares of the company, which has a market capitalization of 647.35 million. As of now, sales total 90,400 K while income totals -126,870 K. Its latest quarter income was 20,250 K while its last quarter net income were -43,840 K.
